Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Teicoplanin vs vancomycin: cost-effectiveness comparisons.

M J Rybak1

  • 1College of Pharmacy, Wayne State University.

Hospital Formulary
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections.

Antimicrobial agents and chemotherapy·2019
Same author

Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.

Antimicrobial agents and chemotherapy·2017
Same author

Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.

Antimicrobial agents and chemotherapy·2014
Same author

Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.

Antimicrobial agents and chemotherapy·2013
Same author

Independent risk factors for the co-colonization of vancomycin-resistant Enterococcus faecalis and methicillin-resistant Staphylococcus aureus in the region most endemic for vancomycin-resistant Staphylococcus aureus isolation.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2013
Same author

Successful treatment of a left ventricular assist device infection with daptomycin non-susceptible methicillin-resistant Staphylococcus aureus: case report and review of the literature.

Transplant infectious disease : an official journal of the Transplantation Society·2012
Same journal

Pharmaceutical industry wins "round one" in protections against product liability claims.

Hospital formulary·1995
Same journal

Safety, efficacy, and lipid profile of doxazosin at a VA medical center.

Hospital formulary·1995
Same journal

A team approach to adverse drug reaction surveillance: success at a tertiary care hospital.

Hospital formulary·1995
Same journal

The drive to reform the FDA gains momentum.

Hospital formulary·1995
Same journal

Who should conduct outcomes research?

Hospital formulary·1995
Same journal

The changing relationship between health care professionals and the pharmaceutical industry.

Hospital formulary·1995
See all related articles

Teicoplanin, a new glycopeptide antibiotic, shows similar efficacy to vancomycin for gram-positive infections. It offers advantages like once-daily dosing and fewer side effects, potentially serving as a vancomycin alternative.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Rising incidence of antibiotic-resistant bacteria, including methicillin-resistant staphylococci and resistant enterococci.
  • Increased reliance on vancomycin for treating serious gram-positive infections.
  • Emergence of novel glycopeptide antibiotics to combat resistant pathogens.

Purpose of the Study:

  • To evaluate teicoplanin as an investigational glycopeptide antibiotic.
  • To compare the efficacy and potential advantages of teicoplanin against vancomycin.
  • To assess the potential role of teicoplanin in clinical practice for gram-positive infections.

Main Methods:

  • Comparative analysis of teicoplanin and vancomycin activity and efficacy.
  • Evaluation of theoretical advantages of teicoplanin, including dosing, side effects, and administration routes.

Related Experiment Videos

  • Assessment of potential clinical applications and formulary acceptance of teicoplanin.

    • Main Results:

    • Teicoplanin demonstrates a similar spectrum of activity and efficacy to vancomycin.
    • Teicoplanin offers theoretical benefits such as once-daily dosing, reduced side effects, and intramuscular administration options.
    • Teicoplanin is unlikely to replace generic vancomycin but may be adopted as an alternative in specific patient populations.

    Conclusions:

    • Teicoplanin presents a viable alternative to vancomycin, particularly for patients with specific needs or intolerances.
    • Its potential advantages in dosing, side effect profile, and administration could lead to wider hospital use.
    • Further understanding of teicoplanin's economic benefits and side effect profile will influence its clinical adoption.